A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Spectrum Pharmaceuticals

Status and phase

Withdrawn

Phase 2

Phase 1

Conditions

Non-Small-Cell Lung Carcinoma

Treatments

Drug: PT-523 for Injection

Study type

Interventional

Funder types

Industry

Identifiers

NCT00112060

HBS101.00

HBS101

Details and patient eligibility

About

This phase I/II, multi-centered, non-randomized trial is designed to determine a safe dose of PT-523 for subjects, and to make preliminary evaluations on the activity of PT-523 as therapy in subjects with NSCLC.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥ 18 years
Histologically or cytologically confirmed NSCLC which is stage III or stage IV, or recurrent disease, and failed therapy with a standard first line (Phase I/II) as well as second line chemotherapy regimen (Phase I), or be intolerant of standard chemotherapy. Receipt of one additional prior chemotherapy regimen for neoadjuvant, adjuvant, or neoadjuvant plus adjuvant is allowable. A prior epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TK) antagonist is allowable (Phase II).
Asymptomatic or treated brain metastases (including steroids) if last therapy was received > 4 weeks from study entry and is deemed by the investigator to have a low likelihood of rapid deterioration.
ECOG performance status 0 - 2.
Adequate organ function and bone marrow reserve.
Use of appropriate contraceptive method.
Signed patient informed consent.

Exclusion criteria

Investigational agents within 30 days prior to Day 1 of study.
Known symptomatic or uncontrolled brain metastases.
Uncontrolled intercurrent illness.
Known human immunodeficiency virus (HIV), hepatitis A, B, C, D and E.
Patient has uncontrolled pleural effusions.
Patient has received nitrosoureas or mitomycin-C within 6 weeks or other chemotherapy or radiation therapy within 3 weeks before study entry.